Abstract: The present invention is related to agents capable of binding to and inhibiting or antagonizing the action of IL-11 and/or or IL-11RA for the treatment and/or prevention of abnormal uterine bleeding, which comprises heavy menstrual bleeding, prolonged bleeding, altered bleeding pattern, dysmenorrhea, as well as of the underlying diseases leiomyoma and endometriosis and the use of the agent to inhibit menstruation. Furthermore, the invention provides novel IL-11 antibodies.

Abstract: A method for starting a grinding tube with an assigned drive device, wherein during the operation of the grinding tube a grinding mode and a charge release mode can be set such that a particularly reliable monitoring of the state of charge located in the grinding tube is ensured, where the grinding tube is rotated and, at a first rotational angle, a first actual torque is detected, a setpoint torque is calculated for a second, relatively large rotational angle based on the first actual torque, an actually occurring, second actual torque is detected when the second rotational angle is reached, an investigation is performed to determine the difference of the second actual torque from the setpoint torque, and the charge release mode of the grinding tube is set when the second actual torque is within the threshold range, otherwise the grinding tube is operated in the grinding mode.

Abstract: A system for monitoring and mitigating client-side exploitation of application flaws includes a server to operate a first application. The first application communicates with a client device operating a second application to execute an application flaw script. The application flaw script causes the client device to produce a first request associated with vulnerability of the first application. An application flaw service module, communicatively coupled to the server, receives the first request from the client device comprising transactional metadata based on the application flaw script and inspects the transactional metadata for malicious content within the first request.

Abstract: A system for monitoring and mitigating client-side exploitation of application flaws includes a server to operate a first application. The first application communicates with a client device operating a second application to execute an application flaw script. The application flaw script causes the client device to produce a first request associated with vulnerability of the first application. An application flaw service module, communicatively coupled to the server, receives the first request from the client device comprising transactional metadata based on the application flaw script and inspects the transactional metadata for malicious content within the first request.

Abstract: The invention relates to novel chemical compounds, pharmaceutically acceptable derivatives thereof, processes for their preparation, pharmaceutical compositions containing them, and to their use in medicine, particularly use in the amelioration of a clinical condition for which a thrombin inhibitor is indicated.